Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)
Key facts
- Who runs it
- Societe ACTIVBIOMAT
- Where
- France7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 340 people enrolled
- Started
- 8 May 2017
- Expected to end
- Dec 2039
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Total Hip Arthroplasty
- Record updated
- 22 December 2025
Who can take part
- Age
- 18 years to 74 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Patients aged over 50 and under 75 years OR aged under 50 years with joint lesions not amenable to successful conservative treatment
- THA following a primary or secondary osteoarthritis
- THA following an aseptic osteonecrosis
- THA following a rapidly destructive osteoarthritis
- Social insurance
- Informed and signed consent
Who cannot take part
- Patients younger than 50 years and with joint lesions that can be successfully treated with conservative treatment
- Long-term corticosteroid treatment
- Surgical history on the affected hip
- Evolving infection of the articulation or peri-articular region involved, including severe neuroarthropathy
- Allergy known to any component of prostheses
- Known hypersensitivity to polystyrene sulfonate resins
- Significant muscle loss, neuromuscular injury or vascular insufficiency of affected limb
- Charcot's disease
- Inflammatory rheumatism
- Tumor Pathology of the hip bone
- Study femoral stem not adapted to the patient's anatomy (verified on preoperative X-rays using Ceraver templates)
- Loss of bone of the joint that makes it impossible to properly anchor a cementless prosthesis
- Acetabular or femoral bone graft associated
- Infectious hip arthritis history
- Native cotyl with a diameter of less than 42mm or greater than 68mm
- Immunocompromised patients
- Difficulties of follow-up (departure on vacation, imminent change, geographical distance, patients not residing in metropolis, insufficient motivation) or understanding of the protocol
- Patient Refusal
- Pregnant and lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The infection rate after Total Hip Arthroplasty (THA) is about 1%. It is a serious condition, with high morbidity, sometimes fatal, requiring costly treatment.
Read full original descriptionShow less
The treatment is difficult because "biofilm" forms very early after the bacterial contamination of the prosthesis.
Prevent infection means reduce or prevent the formation of bacterial biofilm and controlling protein response to allow osseous-integration of the prosthesis.
A new prosthesis was developped, grafted by PolyNaSS (polysodium styrenesulfonate). This bioactive polymer allows to substantially reduce bacterial adhesion and increase biocompatibility and bio-integration in preclinical studies. This first clinical study aims to compare the osseous-integration of this prosthesis to the same prothesis with no grafting.
No previous clinical trial
The 2 groups in the trial
- ACTISURF-CERAFITTreatment being tested
Total hip arthroplasty (CERAFIT) grafted by PolyNass
Treatment: Total Hip Arthroplasty
- CERAFITExisting treatment, for comparison
Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) not grafted by PolyNass
Treatment: Total Hip Arthroplasty
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Non-inferiority Trial Assessing the Osseointegration of THA Grafted by Sodium Polystyrene Sulfonate -PolyNASS- (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)
- Record updated
- 22 December 2025